
Reckitt Partners with Public Health Foundation of India (PHFI) to Drive Transformative Public Health Interventions
Established in 2006, PHFI is a globally recognized public-private initiative that has contributed significantly to building India's public health capacity through education, research, and advocacy. The institution was recently ranked second among schools of public health globally (International Journal of Public Health, March 2024) and has been recognized as an ICMR Collaborating Centre of Excellence.
The partnership brings together Reckitt's deep experience in driving large-scale behavioural change and PHFI's leadership in public health research, education, and policy. Together, the two organizations aim to co-create innovative solutions, strengthen institutional capacity, and document scalable community health models that can be replicated across India.
As part of the collaboration, PHFI will work closely with Reckitt and its civil society partners to validate and document existing outreach programs nationwide. The resulting evidence will be translated into case studies and academic publications to highlight effective, scalable models for health impact.
On the partnership, Professor Sanjay Zodpey, President, Public Health Foundation of India (PHFI), said, 'Partnership between Reckitt and Public Health Foundation of India will develop initiatives responding to community health needs for capacity building, training programs and research to address the public health challenges with a focus on sanitation and hygiene.'
Ravi Bhatnagar, Director, External Affairs and Partnerships, Reckitt – South Asia, said, 'At Reckitt, we believe we achieve more together as trusted partners. Through collaboration, we can collectively drive systemic, long-term positive change. We deeply value this collaboration, which unites PHFI's academic and policy leadership with Reckitt's on-ground experience in driving behavioural change. Hygiene is the foundation of good health, and this partnership marks another meaningful step in our journey to support the vision of Viksit Bharat by 2047. Trusted, purpose-aligned partnerships like this are essential to building a healthier, more resilient India.'
PHFI has established five Indian Institutes of Public Health and contributed more than 4,800 research publications to the field. Its recognition as a global public health leader further showcases the strength it brings to this collaboration to deliver evidence-based health interventions.
With this partnership, Reckitt and PHFI are not only setting a new benchmark for public-private collaboration but also laying the groundwork for transformative change in how India addresses its most pressing health challenges. Grounding interventions in science and scaling them through community action, the partnership aims to deliver lasting improvements in sanitation, hygiene, and public health outcomes. More than a partnership, this is a mission-driven alliance focused on shifting narratives, empowering communities, and reinforcing the foundations of India's public health system. Together, Reckitt and PHFI aim to ensure that access to health and hygiene is a right for all, not a privilege.
About Reckitt
Advertisement
Reckitt* exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege. Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.
Every day, around 30 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always. We are a diverse global team of 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more or get in touch with us at www.reckitt.com.
*Reckitt is the trading name of the Reckitt Benckiser group of companies.
Click here for Media Contact Details
Submit your press release
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
03-08-2025
- Business Wire
RBGLY Deadline: Rosen Law Firm Urges Reckitt Benckiser Group PLC (OTC: RBGLY) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of American Depositary Shares ('ADSs') of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 through July 28, 2024. Reckitt describes itself as a 'U.K.-based consumer goods and health conglomerate.' For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Reckitt Benckiser Group PLC (OTC: RBGLY) Misled Investors Regarding its Business Operations. According to the lawsuit, during the Class Period, defendants failed to warn investors and consumers: (1) that preterm infants were at an increased risk of developing necrotizing enterocolitis ('NEC') by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, defendants' positive statements about Reckitt's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Reckitt Benckiser Group PLC. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 4, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.


Business Upturn
02-08-2025
- Business Upturn
RECKITT (RBGLY) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Reckitt (RBGLY) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Reckitt between January 13, 2021, and July 28, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Reckitt Benckiser Group plc ('Reckitt' or the 'Company') (OTC:RBGLY) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Reckitt securities between January 13, 2021, and July 28, 2024, both dates inclusive (the 'Class Period'). Investors have until August 4, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Reckitt is a United Kingdom-based, global consumer goods company. To date, over 500 state and federal products liability lawsuits have been filed against Reckitt and its competitor, Abbott Laboratories ('Abbott'), claiming that they failed to adequately warn that premature infants consuming cow milk-based formulas, such as Reckitt's Enfamil and Abbott's Similac, have an increased risk of developing necrotizing enterocolitis ('NEC'), a life-threatening intestinal disease that affects premature or low birth weight infants. The Class Action alleges that, during the Class Period, Defendants made misleading statements and omissions regarding the Company's business, financial condition, and prospects. Specifically, Defendants failed to warn investors and consumers: (1) that preterm infants were at an increased risk of developing NEC by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Reckitt shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]


Business Wire
01-08-2025
- Business Wire
RECKITT BENCKISER 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Reckitt Benckiser Group PLC
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC ('Reckitt' or the 'Company') (OTC: RBGLY), if they purchased the Company's American Depositary Shares ('ADSs') between January 13, 2021 and July 28, 2024, inclusive (the 'Class Period'). This action is pending in the United States District Court for the Southern District of New York. What You May Do If you purchased ADSs of Reckitt and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( or visit to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by August 4, 2025. About the Lawsuit Reckitt and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) preterm infants were at an increased risk of developing necrotizing enterocolitis ('NEC') by consuming the Company's cow's milk-based formula, Enfamil; (ii) such risk could impact the Company's sales of Enfamil and expose the Company to legal claims; and (iii) as a result of the foregoing, the Company's positive statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The case is Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., No. 25-cv-4708. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit